Exhibition Report: Participated in the 2nd AMED SCARDA Joint Symposium
From March 17 to 19, 2025, our colleagues Ozawa and Tatsukawa participated in the 2nd AMED SCARDA “Project for Formation of World-Leading Research and Development Centers for Vaccine Development” Joint Symposium, held at the Kobe International Conference Center in Hyogo Prefecture.
This symposium was organized by the Advanced Research & Development Programs Center for Vaccines (SCARDA) of the Japan Agency for Medical Research and Development (AMED), with the aim of sharing the latest research findings and technologies related to vaccine development and further strengthening collaboration.
Our company presented a corporate exhibition and poster under the theme “Autonomous Optimization of Vaccine Development Processes Using AI: Case Studies on Patient Dosing Schedules and Optimal Culture Medium Composition Exploration.” We introduced applications of our solution “Epistra Accelerate” to vaccine development and life sciences, and engaged in active discussions with attendees.
Related Articles
Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of Japan
Epistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
Cell Culture Optimization Software 'CellTune Ver.2' Launches Globally
Epistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine Seminar
On June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.